Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond

The Paradigm Shift: EAST-AFNET 4 Results

For more than two decades, the rate-versus-rhythm debate in atrial fibrillation management was considered settled. AFFIRM and RACE established that rate control was non-inferior to rhythm control for mortality and cardiovascular outcomes, and clinical practice shifted accordingly — many patients with AF received rate control as the default strategy, with rhythm control reserved for those with persistent symptoms. EAST-AFNET 4 challenged that consensus by asking a different question: what if we pursue rhythm control early, before the atria have remodeled, using modern tools that are safer than the antiarrhythmics available in the AFFIRM era? The answer changed how cardiologists, electrophysiologists, and internists think about AF management.

The EAST-AFNET 4 trial enrolled 2,789 patients with early atrial fibrillation (diagnosed within 12 months)[2] and randomized them to early rhythm control versus usual care. Early rhythm control reduced the primary composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome by 21% (HR 0.79, 96% CI 0.66-0.94, p=0.005)[1]. The benefit emerged within the first year and persisted through a median follow-up of 5.1 years, fundamentally challenging the equipoise established by AFFIRM and RACE.

Critically, the safety signal that plagued earlier rhythm control trials was absent. The EAST-AFNET 4 cohort had lower rates of serious adverse events in the rhythm control arm, largely attributable to improved antiarrhythmic drug selection and greater use of catheter ablation compared to historical trials.

Why Early Matters: The Window of Opportunity

The word "early" in EAST-AFNET 4 is the most important detail in the trial. Patients were enrolled within 12 months of AF diagnosis — before the progressive atrial fibrosis, dilation, and electrical remodeling that make long-standing AF increasingly resistant to rhythm control. This is the biological rationale for why EAST-AFNET 4 succeeded where AFFIRM did not: early AF is still reversible in many patients, while AF that has been present for years has fundamentally altered atrial substrate. The clinical implication for the physician diagnosing new AF is clear: the decision about rhythm control should be made now, not deferred to a later appointment. Waiting months to refer for rhythm control may mean missing the window where the benefit is greatest.

DOAC Selection: Practical Considerations

All four DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) demonstrate non-inferior or superior efficacy compared to warfarin for stroke prevention in AF. The ARISTOPHANES study and multiple real-world analyses suggest apixaban may have the most favorable bleeding profile (major bleeding rate 2.1% vs 3.6% for warfarin per year)[3]. For patients with CrCl 15-25 mL/min, apixaban 2.5 mg BID remains the only DOAC with adequate safety data. Dabigatran is the sole DOAC with a specific reversal agent (idarucizumab), while andexanet alfa covers factor Xa inhibitors.

Choosing a DOAC for Your Patient

In practice, the DOAC choice is often driven by renal function, bleeding risk, and patient preference rather than differences in stroke prevention efficacy, which are modest between agents. For the patient with normal renal function and no strong preference, apixaban is a defensible first choice given its favorable bleeding profile. For the patient who wants a once-daily regimen, rivaroxaban or edoxaban provides that convenience. For the patient at high bleeding risk or on dialysis, the data remain limited, and individualized risk-benefit discussion with the patient is essential. The one principle that should not vary: every AF patient with an indication for anticoagulation based on CHA2DS2-VASc score should receive it, regardless of whether rate or rhythm control is pursued. Rhythm control does not eliminate the need for anticoagulation.

Catheter Ablation Outcomes: CABANA and CASTLE-AF

The CABANA trial showed ablation reduced the primary endpoint by 14% in intention-to-treat analysis (HR 0.86, 95% CI 0.65-1.15)[5], but per-protocol analysis favoring ablation reached significance (HR 0.73, p=0.006). CASTLE-AF demonstrated a striking 38% reduction in all-cause mortality with ablation in patients with AF and heart failure (LVEF[4] ≤35%). The RAFT-AF trial confirmed ablation superiority to amiodarone for AF in heart failure, with a 5.4% absolute improvement in LVEF at 24 months[6].

When to Refer for Ablation

The AF patient who benefits most from ablation referral is the one with symptomatic paroxysmal or early persistent AF, preserved or mildly reduced LVEF, a preference for avoiding long-term antiarrhythmic drugs, and access to a high-volume electrophysiology center. For patients with AF and heart failure with reduced ejection fraction, the CASTLE-AF and RAFT-AF data make an even stronger case — ablation is not just a symptom-relief strategy but a treatment that may improve cardiac function and reduce mortality. The patient with AF and worsening HFrEF despite medical optimization should be discussed with electrophysiology regardless of symptom burden from the arrhythmia itself, because the tachycardia-mediated cardiomyopathy component may only become apparent after sinus rhythm is restored.